Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (1165)	6/2/1998 10:27:00 PM
From: Rudy Saucillo	Respond to of 2742

I think the issue is that there simply is no news (that is, public information) to create interest for retail buyers. I'm not going to defend BlueStone's or Galton's performance, but I do believe they are in active discussions with other companies regarding partnership or merger possibilities - exactly what BlueStone is under contract to do. As we've seen in the news recently, there's much activity ongoing with cancer immunotherapy companies as well as vaccine technology companies. I really think the opportunities for partnerships, acquisition, or buy-out are very real and exciting. I hope we see a deal before the current BlueStone contract expires. Rudy